Menu

  • REALITY Study
  • DIRECT trial
  • DEFINITIVE LE study
  • Resources

    • DEFINITIVE LE clinical summary

    The DEFINITIVE LE study is one of the largest multinational, multicenter PAD device studies to date, enrolling 800 patients from 47 sites in the United States and Europe. It provides insight into the clinical utility of directional atherectomy with the TurboHawk™ and SilverHawk™ directional atherectomy devices in a broad range of patients, including diabetics, non-diabetics, claudicants, and those with critical limb ischemia (CLI).

    Read more about the DEFINITIVE LE clinical study in published, peer-reviewed journals:

    DEFINITIVE LE — acute

    Acute Results of Directional Atherectomy for the Treatment of Claudication and Critical Limb Ischemia in the DEFINITIVE LE Study

    DEFINITIVE LE — primary

    Lower Extremity Revascularization Using Directional Atherectomy: 12-month Prospective Results of the DEFINITIVE LE Study

    DEFINITIVE LE — infrapopliteal

    One-year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions: Subgroup Results of the Prospective, Multicenter DEFINITIVE LE Trial

    DEFINITIVE LE — diabetes

    A Comparison of Clinical Outcomes for Diabetic and Nondiabetic Patients Following Directional Atherectomy in the DEFINITIVE LE Claudicant Cohort

    DEFINITIVE Calcium

    Effective Endovascular Treatment of Calcified Femoropopliteal Disease with Directional Atherectomy and Distal Embolic Protection: Final Results of the DEFINITIVE Ca⁺⁺ Trial

    Downloads

    Download these clinical paper reviews and learn more about DEFINITIVE LE results overall.

    Related links

    Related products